What drove the intraday move in IGPH.SW stock?

A volume surge to **2,033,000** shares pushed IGPH.SW stock down **25.0%** to **CHF0.0015** on 17 Feb 2026, amplifying price moves in a thinly traded micro-cap healthcare name on SIX.

What is Meyka AI's view on IGPH.SW stock?

Meyka AI rates IGPH.SW **62.41/100 (B, HOLD)** and projects a baseline **CHF0.0025** in 12 months, noting high volatility and balance-sheet risk; forecasts are model-based, not guarantees.

Is IGPH.SW stock suitable for long-term investors?

IGPH.SW stock shows negative EPS, low cash per share, and a small market cap, which raises dilution risk. Long-term investors should demand clear revenue growth and funding clarity before adding exposure.

How should traders manage risk with IGPH.SW stock?

Use small position sizes, set strict stop-loss levels, trade around confirmed volume spikes, and avoid carrying large overnight positions due to low liquidity and wide spreads.

CH Stocks

IGPH.SW down 25% to CHF0.0015 on heavy volume (SIX) 17 Feb 2026: intraday most active

ByHuzaifa Zahoor February 17, 2026

We saw IGPH.SW stock drop 25.0% to CHF0.0015 on the intraday session at the SIX on 17 Feb 2026, driven by a surge in volume to 2,033,000 shares. The move made IGEA Pharma N.V. one of the most active names on the Swiss board during the morning trade. Price fell from the previous close of CHF0.0020 and traded between CHF0.0015 and CHF0.0020 intraday. We focus on liquidity, valuation, Meyka AI grading, and forward scenarios for traders watching small-cap healthcare names in Switzerland.